JP2018526325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526325A5 JP2018526325A5 JP2017563568A JP2017563568A JP2018526325A5 JP 2018526325 A5 JP2018526325 A5 JP 2018526325A5 JP 2017563568 A JP2017563568 A JP 2017563568A JP 2017563568 A JP2017563568 A JP 2017563568A JP 2018526325 A5 JP2018526325 A5 JP 2018526325A5
- Authority
- JP
- Japan
- Prior art keywords
- topical pharmaceutical
- pharmaceutical composition
- concentration
- weight
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 15
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000565 tazarotene Drugs 0.000 claims description 4
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 12
- -1 The including Substances 0.000 claims 5
- 229960001631 Carbomer Drugs 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 229920001888 polyacrylic acid Polymers 0.000 claims 4
- BDSYKGHYMJNPAB-LICBFIPMSA-N [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims 3
- 229940048498 halobetasol propionate Drugs 0.000 claims 3
- 229950008396 ulobetasol propionate Drugs 0.000 claims 3
- ONKUXPIBXRRIDU-UHFFFAOYSA-N diethyl decanedioate Chemical compound CCOC(=O)CCCCCCCCC(=O)OCC ONKUXPIBXRRIDU-UHFFFAOYSA-N 0.000 claims 2
- 229920001519 homopolymer Polymers 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 2
- LEHFPXVYPMWYQD-XHIJKXOTSA-N Ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IQIBKLWBVJPOQO-UHFFFAOYSA-N tazarotenic acid Chemical class C1=C2C(C)(C)CCSC2=CC=C1C#CC1=CC=C(C(O)=O)C=N1 IQIBKLWBVJPOQO-UHFFFAOYSA-N 0.000 description 1
Description
さらに別の態様において、本発明は、（ａ）ハロベタゾールまたはその薬学的に許容される塩またはエステル、および（ｂ）タザロテンまたはその薬学的に許容されるタザロテン酸塩またはエステルの組合せを含む医薬組成物で乾癬を局所的に治療する方法であって、その組成物が、６週間または８週間などの少なくとも４週間に亘り一日少なくとも一回塗布される、方法を提供する。
Claims (11)
- 乾癬を治療するための局所用医薬組成物であって、該組成物が、
（ａ）前記組成物の０．００５〜０．０３質量％の濃度でのプロピオン酸ハロベタゾール、
（ｂ）前記組成物の０．０３〜０．０４９質量％の濃度でのタザロテン、および
（ｃ）皮膚科学的に許容される担体、
を含む、局所用医薬組成物。 - （ａ）前記組成物の０．０１質量％の濃度のプロピオン酸ハロベタゾール、および
（ｂ）該組成物の０．０４５質量％の濃度のタザロテン、
を含む、請求項１記載の局所用医薬組成物。 - 前記組成物が水中油エマルションである、請求項１または２記載の局所用医薬組成物。
- 前記プロピオン酸ハロベタゾールおよび前記タザロテンが、前記エマルションの液体油成分中に溶けている、請求項３記載の局所用医薬組成物。
- 前記液体油成分が、ジカルボン酸エステル（ＤＣＡＥ）、モノカルボン酸エステル（ＭＣＡＥ）、またはそれらの組合せを含む、請求項４記載の局所用医薬組成物。
- 前記液体油成分が、ジカルボン酸エステル（ＤＣＡＥ）、モノカルボン酸エステル（ＭＣＡＥ）、それらの組合せ、およびそれらの混合物からなる群より選択される、請求項４記載の局所用医薬組成物。
- 前記水中油エマルションの油相が、セバシン酸ジエチルおよび軽油を含む液体油成分を含む、請求項３記載の局所用医薬組成物。
- 前記エマルションがローションである、請求項３記載の局所用医薬組成物。
- 前記エマルションがクリームである、請求項３記載の局所用医薬組成物。
- 前記エマルションの水相が、カルボマーコポリマータイプＢおよびカルボマーホモポリマータイプＡを含む、請求項７記載の局所用医薬組成物。
- 前記セバシン酸ジエチルが前記組成物の２．５〜３．５質量％の濃度で存在し、前記軽油が前記組成物の７．５〜８．５質量％の濃度で存在し、前記カルボマーコポリマータイプＢが前記組成物の０．３〜０．５質量％の濃度で存在し、前記カルボマーホモポリマータイプＡが前記組成物の０．５〜０．７質量％の濃度で存在する、請求項１０記載の局所用医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181481P | 2015-06-18 | 2015-06-18 | |
| US62/181,481 | 2015-06-18 | ||
| PCT/US2016/035991 WO2016205001A1 (en) | 2015-06-18 | 2016-06-06 | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526325A JP2018526325A (ja) | 2018-09-13 |
| JP2018526325A5 true JP2018526325A5 (ja) | 2019-07-11 |
| JP6997624B2 JP6997624B2 (ja) | 2022-01-17 |
Family
ID=56131662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563568A Active JP6997624B2 (ja) | 2015-06-18 | 2016-06-06 | 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US10251895B2 (ja) |
| EP (1) | EP3310389B1 (ja) |
| JP (1) | JP6997624B2 (ja) |
| KR (2) | KR102643849B1 (ja) |
| CN (1) | CN108282998B (ja) |
| AU (1) | AU2016279801B2 (ja) |
| BR (1) | BR112017027332B1 (ja) |
| CA (1) | CA2988577A1 (ja) |
| CY (1) | CY1123354T1 (ja) |
| DK (1) | DK3310389T3 (ja) |
| ES (1) | ES2812451T3 (ja) |
| HR (1) | HRP20201250T1 (ja) |
| HU (1) | HUE050603T2 (ja) |
| LT (1) | LT3310389T (ja) |
| MX (1) | MX2017015990A (ja) |
| PL (1) | PL3310389T3 (ja) |
| PT (1) | PT3310389T (ja) |
| RS (1) | RS60672B1 (ja) |
| SI (1) | SI3310389T1 (ja) |
| WO (1) | WO2016205001A1 (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
| WO2016205001A1 (en) | 2015-06-18 | 2016-12-22 | Valeant Pharmaceuticals North America | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis |
| EA034808B1 (ru) * | 2015-07-13 | 2020-03-24 | Др. Редди'С Лабораториз Лтд. | Ретиноидные композиции для местного применения |
| US11311482B2 (en) | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
| BR112019023817A8 (pt) * | 2017-05-12 | 2022-12-06 | Bausch Health Us Llc | Composições tópicas e métodos para o tratamento de doenças da pele |
| AU2018288256B2 (en) * | 2017-06-23 | 2023-09-28 | Laboratorios Salvat, S.A. | An oil-in-water nanoemulsion composition of clobetasol |
| US10653656B2 (en) * | 2018-04-05 | 2020-05-19 | Bausch Health Ireland Limited | Topical pharmaceutical compositions for treating skin conditions |
| US11364198B2 (en) * | 2018-04-05 | 2022-06-21 | Bausch Health Ireland Limited | Polymeric emulsion delivery systems |
| US10945952B2 (en) | 2019-03-14 | 2021-03-16 | Crescita Therapeutics Inc. | Rinse-off compositions and uses thereof for delivery of active agents |
| KR102327827B1 (ko) | 2019-11-01 | 2021-11-18 | 한국과학기술연구원 | 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물 |
| CN113116891B (zh) * | 2019-12-30 | 2024-07-16 | 重庆华邦制药有限公司 | 一种乳膏及其制备方法 |
| KR102527907B1 (ko) | 2020-09-14 | 2023-05-03 | 한국과학기술연구원 | 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR102461001B1 (ko) | 2020-09-14 | 2022-11-01 | 한국과학기술연구원 | 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR102451304B1 (ko) | 2020-09-14 | 2022-10-07 | 한국과학기술연구원 | 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR20230041255A (ko) | 2021-09-17 | 2023-03-24 | 한국과학기술연구원 | 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR102692893B1 (ko) | 2021-09-17 | 2024-08-08 | 한국과학기술연구원 | 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물 |
| CN113975249B (zh) * | 2021-10-14 | 2023-01-03 | 中山大学·深圳 | Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用 |
| CN113712918A (zh) * | 2021-10-28 | 2021-11-30 | 济南纽华医药科技有限公司 | 一种阿普斯特微乳及其制备方法 |
| WO2024141639A1 (en) * | 2022-12-31 | 2024-07-04 | Bausch Health Ireland Limited | Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU75903A1 (ja) | 1976-09-29 | 1978-05-16 | ||
| NL7105591A (en) | 1971-04-24 | 1972-10-26 | Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4- | |
| DE2655570A1 (de) | 1975-12-12 | 1977-06-16 | Ciba Geigy Ag | Neue polyhalogensteroide und verfahren zu ihrer herstellung |
| US4048310A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid formulation in form of lotion or cream |
| US4083974A (en) | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
| JPS5850964B2 (ja) | 1978-03-07 | 1983-11-14 | 東興薬品工業株式会社 | ステロイド含有クリ−ム製剤およびその製造方法 |
| US4299828A (en) | 1979-05-31 | 1981-11-10 | E. R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
| AU5794680A (en) | 1979-05-31 | 1980-12-04 | E.R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
| US4233295A (en) | 1979-05-31 | 1980-11-11 | E. R. Squibb & Sons, Inc. | Corticosteroid formulations containing sebacate carrier |
| PT73772B (en) | 1980-10-06 | 1983-10-14 | Glaxo Group Ltd | Topically administrable pharmaceutical compositions containing anti-inflammatory steroids |
| JPS58225009A (ja) | 1982-06-23 | 1983-12-27 | Shionogi & Co Ltd | コルチコステロイド外用製剤 |
| DE3225848A1 (de) | 1982-07-07 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Kortikoidhaltige zubereitung zur topischen applikation |
| GB8401965D0 (en) | 1984-01-25 | 1984-02-29 | Beecham Group Plc | Composition |
| CA1303991C (en) | 1986-03-31 | 1992-06-23 | Chung H. Cheng | Composition and method for delivering a steroid active ingredient |
| US5019569A (en) | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
| JPH0676327B2 (ja) | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイド軟膏製剤 |
| JPH0676328B2 (ja) | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイドクリ−ム製剤 |
| JPH07116026B2 (ja) | 1987-07-07 | 1995-12-13 | 株式会社資生堂 | ジクロフェナックナトリウム含有乳化外用剤 |
| WO1991008733A1 (en) | 1989-12-20 | 1991-06-27 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
| EP0471084B1 (en) | 1990-03-02 | 1996-01-10 | Shiseido Company Limited | Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic |
| TW218849B (ja) * | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| EP0969847A1 (en) | 1997-02-20 | 2000-01-12 | Allergan Sales, Inc. | Tazarotene and corticosteroid treatment for psoriasis |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| GB9823036D0 (en) | 1998-10-22 | 1998-12-16 | Glaxo Group Ltd | Fluticasone lotion having improved vasoconstrictor activity |
| WO2000047211A1 (en) * | 1999-02-12 | 2000-08-17 | Susan Bershad | Short contact treatment of psoriasis with topical retinoids |
| US6730308B1 (en) * | 1999-03-08 | 2004-05-04 | Allergan, Inc. | Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage |
| US6656928B1 (en) | 1999-09-02 | 2003-12-02 | Mccadden Michael E. | Composition for the topical treatment of rashes, dermatoses and lesions |
| US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| CA2423930C (en) * | 2000-10-27 | 2009-11-24 | Leo Pharma A/S | Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid |
| US6709663B2 (en) | 2001-08-31 | 2004-03-23 | Healthpoint, Ltd. | Multivesicular emulsion drug delivery systems |
| US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
| US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| CN1210034C (zh) * | 2002-12-06 | 2005-07-13 | 重庆华邦制药股份有限公司 | 治疗银屑病的药物组合物 |
| AU2003302305A1 (en) | 2002-12-31 | 2004-07-22 | Sachin S Bhagwat | Benzoquinolizine-2-carboxylic acid-containing compositions |
| JP2004359585A (ja) | 2003-06-03 | 2004-12-24 | Medorekkusu:Kk | 被膜形成型の副腎皮質ステロイド薬含有外用製剤 |
| CN1210035C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗银屑病的复方外用药物 |
| CN1210041C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗痤疮的复方外用药物 |
| US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| CA2601123A1 (en) | 2005-03-15 | 2006-09-21 | Kyowa Hakko Kogyo Co., Ltd. | External preparation |
| TW200740441A (en) * | 2005-06-17 | 2007-11-01 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
| JP2009519956A (ja) | 2005-12-14 | 2009-05-21 | ザーズ， インコーポレイテッド | 薬物の皮膚送達のための組成物および方法 |
| WO2008038147A2 (en) | 2006-07-05 | 2008-04-03 | Foamix Ltd. | Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof |
| WO2008152444A2 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| RU2470645C2 (ru) | 2007-09-10 | 2012-12-27 | Гленмарк Фармасьютикалс Лимитед | Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида |
| WO2009084020A2 (en) | 2007-10-18 | 2009-07-09 | Glenmark Pharmaceuticals Limited | Topical composition comprising halobetasol and salicylic acid |
| BRPI0914630A2 (pt) | 2008-06-26 | 2019-09-24 | Anterios Inc | liberação dérmica |
| PT2400951T (pt) * | 2009-02-25 | 2018-11-26 | Mayne Pharma Llc | Composições de espuma tópica |
| US20130310355A1 (en) | 2009-12-15 | 2013-11-21 | Young Pharmaceuticals, Inc. | Low toxicity topical active agent delivery system |
| US9782341B2 (en) | 2010-10-15 | 2017-10-10 | John E. Kulesza | Delivery of hydrophobic bioactive agents |
| US20120115821A1 (en) * | 2010-11-04 | 2012-05-10 | 442 Ventures, Llc | Composition and method for treating skin conditions |
| US8809307B2 (en) * | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
| US9034926B2 (en) * | 2010-12-30 | 2015-05-19 | Nicholas V. Perricone | Topical nitrone spin trap compositions for psoriasis |
| TW201311295A (zh) | 2011-06-03 | 2013-03-16 | Allergan Inc | 對皮脂腺之類視色素化合物之目標遞送 |
| WO2013104399A1 (en) * | 2012-01-09 | 2013-07-18 | Almirall, S.A. | Topical pharmaceutical compositions comprising bexarotene and a corticosteroids |
| US8962028B2 (en) | 2012-10-18 | 2015-02-24 | MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company | Topical steroid composition and method |
| CN104288157B (zh) * | 2013-01-29 | 2018-04-13 | 江苏知原药业有限公司 | 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法 |
| RU2016115481A (ru) * | 2013-09-25 | 2017-10-30 | Сан Фармасьютикал Индастриз Лимитед | Композиция галобетазола для местного спрея |
| US20190133943A1 (en) | 2015-06-18 | 2019-05-09 | Valeant Pharmaceuticals North America | Topical compositions and methods for treating skin diseases |
| WO2016205001A1 (en) | 2015-06-18 | 2016-12-22 | Valeant Pharmaceuticals North America | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis |
| US11311482B2 (en) | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
| BR112019023817A8 (pt) | 2017-05-12 | 2022-12-06 | Bausch Health Us Llc | Composições tópicas e métodos para o tratamento de doenças da pele |
-
2016
- 2016-06-06 WO PCT/US2016/035991 patent/WO2016205001A1/en active Application Filing
- 2016-06-06 ES ES16729470T patent/ES2812451T3/es active Active
- 2016-06-06 DK DK16729470.1T patent/DK3310389T3/da active
- 2016-06-06 JP JP2017563568A patent/JP6997624B2/ja active Active
- 2016-06-06 BR BR112017027332-2A patent/BR112017027332B1/pt active IP Right Grant
- 2016-06-06 CN CN201680035629.7A patent/CN108282998B/zh active Active
- 2016-06-06 US US15/173,961 patent/US10251895B2/en active Active
- 2016-06-06 HU HUE16729470A patent/HUE050603T2/hu unknown
- 2016-06-06 AU AU2016279801A patent/AU2016279801B2/en active Active
- 2016-06-06 SI SI201630936T patent/SI3310389T1/sl unknown
- 2016-06-06 KR KR1020187001229A patent/KR102643849B1/ko active IP Right Grant
- 2016-06-06 KR KR1020247006984A patent/KR20240035898A/ko active Search and Examination
- 2016-06-06 PL PL16729470T patent/PL3310389T3/pl unknown
- 2016-06-06 MX MX2017015990A patent/MX2017015990A/es active IP Right Grant
- 2016-06-06 EP EP16729470.1A patent/EP3310389B1/en active Active
- 2016-06-06 LT LTEP16729470.1T patent/LT3310389T/lt unknown
- 2016-06-06 PT PT167294701T patent/PT3310389T/pt unknown
- 2016-06-06 RS RS20200997A patent/RS60672B1/sr unknown
- 2016-06-06 CA CA2988577A patent/CA2988577A1/en active Pending
-
2018
- 2018-02-23 US US15/903,785 patent/US10426787B2/en active Active
-
2019
- 2019-04-08 US US16/377,540 patent/US20190231797A1/en not_active Abandoned
-
2020
- 2020-08-04 CY CY20201100719T patent/CY1123354T1/el unknown
- 2020-08-10 HR HRP20201250TT patent/HRP20201250T1/hr unknown
-
2021
- 2021-01-21 US US17/154,591 patent/US11679115B2/en active Active
- 2021-07-02 US US17/366,871 patent/US11679116B2/en active Active
-
2022
- 2022-11-23 US US17/993,817 patent/US11648256B2/en active Active
-
2023
- 2023-05-04 US US18/312,162 patent/US20230355640A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526325A5 (ja) | ||
| HRP20201250T1 (hr) | Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze | |
| HRP20192202T1 (hr) | Acc inhibitori i njihove upotrebe | |
| WO2016071293A3 (en) | Pharmaceutical compound | |
| JP2014129360A5 (ja) | ||
| JP2016511753A5 (ja) | ||
| JP2012131827A5 (ja) | ||
| JP2018531941A5 (ja) | ||
| EA201990455A1 (ru) | КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
| JP2017533930A5 (ja) | ||
| FI2887923T3 (fi) | Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito | |
| RU2017125963A (ru) | Способ повышения устойчивости композиции, содержащей омега-6 полиненасыщенные жирные кислоты | |
| WO2018209363A3 (en) | PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE | |
| JP2014509655A5 (ja) | ||
| RU2020137385A (ru) | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина | |
| JP2020011967A5 (ja) | ||
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| RU2016129193A (ru) | Составы на основе берберина и их применение | |
| JP2015030689A5 (ja) | ||
| WO2015011120A3 (en) | Salts of dasatinib in crystalline form | |
| HRP20161135T1 (hr) | Oblici u krutom stanju n-((s)-2,3-dihidroksi-propil)-3-(2-fluoro-4-jodo-fenilamino)-izonikotinamida | |
| JP2015504860A5 (ja) | ||
| JP2016527319A5 (ja) | ||
| JP2020519656A5 (ja) | ||
| WO2012119861A3 (en) | Use of a 2-methylsuccinic acid diester derivative as solvent in cosmetic compositions; cosmetic compositions containing the same |